Efficacy of Chinese traditional quadruple single pill combination versus valsartan/hydrochlorothiazide for the treatment of hypertension (COSPQ-BP): study protocol for randomised c... by Kai Liu, Yu Yan, Xin Zhang, Yanan Li, Yuanyuan Yao, Lu Liu, Runyu Ye, Si Wang, Xiangyu Yang, Xiaoping Chen, Shanshan Jia, Qingtao Meng, Xianghao Zuo

“…The secondary outcomes have been predetermined and will primarily encompass the following: (1) changes in other BP measures, as well as changes in blood lipids, blood glucose and uric acid at 12 weeks and (2) evaluation of the impact of starting antihypertensive therapy with compound reserpine and triamterene tablets or valsartan/hydrochlorothiazide on the depressive and anxiety statess of patients.Ethics and dissemination The study protocol (version number: V5.0, version date: 17 January 2023) has been approved by the ethics committee (Biomedical Ethics Committee of West China Hospital of Sichuan University, approval number: Review (51) in 2023). …”
Get full text

Safety profile of sacituzumab govitecan in patients with breast cancer: A systematic review and meta-analysis by Maria Inez Dacoregio, Isabella Michelon, Caio Ernesto do Rego Castro, Francisco Cezar Aquino de Moraes, Guilherme Rossato de Almeida, Lis Victória Ravani, Maysa Vilbert, Ricardo Lima Barros Costa

“…Most patients had triple negative BC (54.4 %, n = 505), metastatic disease (89.8 %, n = 833), and were heavily pretreated (at least two lines of prior therapy). Most common all-grade adverse events (AEs) were: neutropenia (70 %, 95 % CI, 64–76 %), followed by nausea (62 %, 95 % CI, 55–68 %), diarrhea (54 %, 95 % CI 47–60 %) and anemia (51 %, 95 % CI, 38–65 %). …”
Get full text

Peripheral versus central cannulation of VA-ECMO for primary graft dysfunction after heart transplantation: A systematic review and meta-analysis by Eduard Ródenas-Alesina, MD, Aleix Olivella, MD, Ani Orchanian-Cheff, MiST, Farid Foroutan, PhD, Yasbanoo Moayedi, MD, MSc, Vivek Rao, MD, PhD, Filio Billia, MD, PhD, Heather J. Ross, MD, MHSc, Ana Carolina Alba, MD, PhD, Natasha Aleksova, MD, MSc

“…Peripheral cannulation decreased the risk of bleeding but increased the risk of limb ischemia and infection, with similar rates of stroke and need for renal replacement therapy. Overall, certainty of evidence was low. Conclusions: With low certainty evidence, peripheral VA-ECMO cannulation may reduce short-term and 1-year mortality with lower bleeding rates but higher limb-related complications, supporting peripheral configuration in HT recipients with severe PGD.…”
Get full text

Characteristics, clinical manifestations and management of leprosy in KwaZulu-Natal, South Africa: A 20-year retrospective study by J S Sons, Z N Mkhize, N C Dlova, C Aldous, P R Bhat, A V Chateau

“…Despite initiation of multidrug therapy in most patients, a significant proportion (27.3%) did not complete the full course of treatment, and treatment reactions were noted in 33.5% of patients. …”
Get full text

Implementasi Data Mining untuk Deteksi Penyakit Ginjal Kronis (PGK) menggunakan K-Nearest Neighbor (KNN) dengan Backward Elimination by Ikhsan Wisnuadji Gamadarenda, Indra Waspada

“…Allowing CKD to be prevented, addressed, and advised to get effective therapy is greater if acknowledged earlier. The process of this research uses work methods of Data Mining Knowledge Data Discovery (KDD). …”
Get full text

Prediction of major adverse cardiovascular events following ST-segment elevation myocardial infarction using cardiac obesity marker—epicardial adipose tissue mass index: a prospect... by Zeyan Liu, Jinbo Wang, Yanfang Yang, Jinglin Cheng, Min Yang, Ye Zhang

“…BackgroundAlthough reperfusion therapy has led to improvements in the acute phase of ST-segment elevation myocardial infarction (STEMI), the incidence of major adverse cardiovascular events (MACE) following STEMI has not significantly decreased. …”
Get full text

Ethnobotanical survey of medicinal plants used in management of breast cancers in Qatar by Rasha.S.Abo El Alaa, Hend Al-Jaber, Fatima Al Zahraa Chokor, Abdullah A. Shaito, Layla Al-Mansoori

“…In conclusion, our study on herbalists' recommendations for breast cancer documents the traditional practices for patient therapy in Qatar. Saussurea costus (Falc.) Lipsch. …”
Get full text

Types of electronic nicotine delivery systems (ENDS) used by people of different age and smoking status groups: results from a US nationally representative survey by Lucy Popova, Robert T Fairman, David L Ashley, Zachary B Massey, Bai Cham, Ruiyan Luo, Mohammed Alqahtani, Scott Weaver

Get full text

Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic eve... by Raffaele De Caterina, Kurt Huber, Richard Schilling, Miklos Rohla, Thomas W Weiss, Ladislav Pecen, Giuseppe Patti, Jolanta M Siller-Matula, Renate B Schnabel, Dipak Kotecha, Markus Lucerna, Paulus Kirchhof

“…The incidence of thromboembolic and major bleeding events was 2.34% (95% CI 1.93% to 2.74%) and 2.84% (95% CI 2.41% to 3.33%) after 1-year of follow-up, respectively.Abnormal liver function, prior stroke or transient ischaemic attack, labile international normalised ratio (INR), concomitant therapy with antiplatelet or non-steroidal anti-inflammatory drugs, heart failure and older age (≥75 years) were independently associated with both thromboembolic and major bleeding events.With the exception of unstable INR values, these risk factors were validated in patients treated with NOACs (PREFER in AF Prolongation Study, 72±9 years, 40% female, CHA2DS2-VASc 3.3±1.6). …”
Get full text

Breaking the biofilm barrier: Juglone derivatives as dual-action inhibitors and anti-quorum sensing agents by Muhammad Abdullah Bhatti, Atif Ali Khan Khalil, Sayed Muhammad Ata Ullah Shah Bukhari, Faisal Hanif, Mi-Jeong Ahn, Sumra Wajid Abbasi, Nazir Ahmed Lone, Wen-Jun Li, Wasim Sajjad

“…Conclusion: our results demonstrated the potential of juglone derivatives from R. japonica as a promising anti-biofilm agent and as quorum quencher for future therapy to combat multi-drug resistant infections in particular MRSA.…”
Get full text

Hyssopus cuspidatus volatile oil: a potential treatment for steroid-resistant asthma via inhibition of neutrophil extracellular traps by Xu Wang, Hui-Ming Peng, Meng-Ru Zhang, Jing-Jing Li, Chuan-Peng Zhao, Ya-Li Zhang, Si-Yu Wang, Si-Ying Zhu, Jian-Kang Lu, Hai-Long Yin, Qiang Yin, Jin-Bo Fang

“…Abstract Background Steroid-resistant asthma (SRA) is a form of asthma resistant to corticosteroid therapy, which is characterized by the presence of neutrophil-predominant inflammatory response and neutrophil extracellular traps (NETs) formation. …”
Get full text

Long-term outcomes of robot-assisted versus minimally invasive esophagectomy in patients with thoracic esophageal cancer: a propensity score-matched study by Toru Sakurai, Akihiro Hoshino, Kenta Miyoshi, Erika Yamada, Masaya Enomoto, Junichi Mazaki, Hiroshi Kuwabara, Kenichi Iwasaki, Yoshihiro Ota, Shingo Tachibana, Yutaka Hayashi, Tetsuo Ishizaki, Yuichi Nagakawa

“…These variables included age, sex, body mass index, alcohol consumption, smoking history, American Society of Anesthesiologists stage, comorbidities, tumor location, histology, clinical TNM stage, and preoperative therapy. The primary endpoint was 5-year overall survival (OS), and the secondary endpoints were 5-year disease-free survival (DFS) and recurrence rates. …”
Get full text

Effect of rhGH treatment on lipidome and brown fat activity in prepuberal small for gestational age children: a pilot study by Lorena González, Carolina Gonzalez-Riano, Pablo Fernández-García, Rubén Cereijo, Aina Valls, Andrea Soria-Gondek, Nativitat Real, Belén Requena, Joan Bel-Comos, Patricia Corrales, David Jiménez-Pavón, Coral Barbas, Francesc Villarroya, David Sánchez-Infantes, Marta Murillo

“…Abstract Recombinant human growth hormone (rhGH) therapy is the primary treatment for children born small for gestational age (SGA) who fail to show spontaneous catch-up growth by two or four years. …”
Get full text

A stratified two-stage tumor molecular profiling algorithm to identify clinically actionable molecular alterations in pancreatic cancer☆ by S. Hussung, D. Akhoundova, C. Pistoni, D. Lenggenhager, A. Töpfer, C. Pauli, B. Pestalozzi, C. Britschgi, M. Zoche, M. Rechsteiner, H. Moch, A. Weber, R. Fritsch

“…Patients receiving targeted therapy based on molecular profile showed superior survival (progression-free survival, overall survival) compared with patients without targeted treatment. …”
Get full text

Acute fibrinous and organizing pneumonia after lung transplantation: A case report of treatment with infliximab and tocilizumab and literature review by Christophe Abellan, Foteini Ioakeim, Alessio Casutt, Benoit Lechartier, Zisis Balmpouzis, Samuel Rotman, Leslie Noirez, Isabelle Rochat, John-David Aubert, Angela Koutsokera

“…Furthermore, we propose prompt realization of a cytokine panel analysis in both blood and bronchoalveolar lavage to better guide the adjuvant administration of a targeted anti-inflammatory therapy.…”
Get full text

Real-world treatment patterns and clinical characteristics in patients with moderate-to-severe systemic lupus erythematosus: an analysis of the SLE Prospective Observational Cohort... by Raj Tummala, Richard A Furie, Laurent Arnaud, Eric F Morand, Martin Aringer, Stephanie Chen, Barnabas Desta, Alberta Hoi, Bo Ding, Christine Peschken, Jonatan Hedberg, Tina Grünfeld Eén, Alessandro Sorrentino, Danuta Kielar

“…In subgroup analyses, patients with high IFNGS and high disease activity state (HDAS) at baseline used more immunosuppressants and glucocorticoids compared with those with low IFNGS and non-HDAS at baseline.Conclusions These findings underscore that SLE therapy is still often unable to reach goals as recommended by the European Alliance of Associations for Rheumatology, both with regard to glucocorticoid use and disease activity, suggesting that there is an unmet need for new treatment options for patients with SLE.Trial registration number NCT03189875; 16 June 2017.…”
Get full text

Polybrominated Dibenzo-p-dioxins/Furans (PBDD/Fs) and Diphenyl Ethers (PBDEs) in the Indoor and Outdoor of Gymnasiums by Ching-Kai Su, Jian-He Lu, How-Ran Chao, Wei-Hsiang Chang, Ming-Hsien Tsai, Chih-Lung Wang, I-Cheng Lu, Yu-Ting Chang, Hsiao-Chi Chuang, Wan-Nurdiyana-Wan Mansor, Yi-Chyun Hsu, Ying-I Tsai, Shang-Ming Ma

Get full text

Policy brief: Optimising antimicrobial usage in paediatric inpatient hospital settings by J Cloete, M Karsas, T Chetty, A Pillay, M Archary, D Moore, T Reddy, Y Balakrishna, F Nakwa, R Lancaster, A Goga, P Jeena

“…These include implementing standardized policies for empiric antimicrobial use, routine review of antimicrobial therapy, age-specific antimicrobial stewardship programs, and continued collaborative efforts and research. …”
Get full text

TARGET Protein: the effect of augmented administration of enteral protein to critically ill adults on clinical outcomes—statistical analysis plan for a cluster randomized, cross-se... by Sophie Zaloumis, Matthew J. Summers, Jeffrey J. Presneill, Rinaldo Bellomo, Lee-anne S. Chapple, Marianne J. Chapman, Adam M. Deane, Suzie Ferrie, Craig French, Sally Hurford, Nima Kakho, Matthew J. Maiden, Stephanie N. O’Connor, Sandra L. Peake, Emma J. Ridley, An Tran-Duy, Patricia J. Williams, Paul J. Young, Amalia Karahalios, on behalf of the TARGET Protein Investigators, the Australian, New Zealand Intensive Care Society Clinical Trials Group

“…Secondary outcomes include proportion of patients alive at day 90, survivor-only analysis of days free of the index hospital at day 90, duration of invasive ventilation, ICU and hospital length of stay, incidence of tracheostomy insertion, renal replacement therapy, and discharge destination. The statistical methods and models which will be used to estimate the effects for the primary and secondary outcomes are described. …”
Get full text

Diagnostics and treatment of Clostridium difficile-associated disease: Guidelines of the Russian gastroenterological association by V. T. Ivashkin, N. D. Yushchuk, I. V. Mayev, Tatyana L Lapina, Ye. A. Poluektova, O. S. Shifrin, A. S. Tertychny, A. S. Trukhmanov, A. A. Sheptulin, Ye. K. Baranskaya, O. S. Lyashenko, K. V. Ivashkin

“…Risk factors of C. difficile-associated include antibacterial therapy, hospital admission, elderly age, comorbidity and immunosuppressive treatment. …”
Get full text